Drug Profile
LY 2795050
Alternative Names: 11C-LY2795050; LY2795050Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; New York University School of Medicine; Yale University
- Class Imaging agents
- Mechanism of Action Opioid kappa receptor antagonists; Positron-emission tomography enhancers; Radiography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Major depressive disorder(Diagnosis) in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Post-traumatic-stress-disorder(Diagnosis) in USA (Parenteral)
- 01 Mar 2012 Clinical trials in Diagnostic imaging in USA (Parenteral)